Side by side
CJC-1295 vs IGF-1 LR3
Both are discussed for muscle & performance. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| CJC-1295 | IGF-1 LR3 | |
|---|---|---|
| What it is | A GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude. | A modified insulin-like growth factor engineered to last far longer in the body than the natural hormone. It can cause hypoglycaemia, which makes it the most acutely dangerous compound on this site. |
| EvidenceHow much human evidence exists, not how well it works. | Early human trials | Preclinical |
| Regulatory statusReviewed 2026-08-12 | Not approved for human use in the United States. The FDA has identified CJC-1295 as a substance raising concerns for use in compounded preparations. Sold only as a research chemical. | Not approved for human use in any jurisdiction, and never studied in a human trial. Recombinant IGF-1 itself (mecasermin) is approved for severe primary IGF-1 deficiency, and its labelling carries an explicit hypoglycaemia warning. That warning is the closest thing to clinical safety information this class has. |
| Routes | Subcutaneous | Subcutaneous, Intramuscular |
| Half-life | 0.5 hours | 24 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $2.40/mg | $32.50/mg |
| Median per mg | $7.25/mg | $79.00/mg |
| Vendors with a price | 40 | 32 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. | Refrigerated at 2–8 °C. Do not freeze once mixed. Larger proteins are less forgiving of temperature swings than short peptides. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.